×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TLSA – tiziana life sciences ltd - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TLSA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
07:00 am
tlsa
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
Medium
Report
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
11/25
08:30 am
tlsa
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
Medium
Report
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
11/13
08:30 am
tlsa
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
High
Report
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
10/29
07:00 am
tlsa
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Medium
Report
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
9/30
08:30 am
tlsa
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
Low
Report
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
9/25
08:30 am
tlsa
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
Medium
Report
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
9/24
08:56 am
tlsa
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress [Yahoo! Finance]
Medium
Report
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress [Yahoo! Finance]
9/24
08:30 am
tlsa
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
High
Report
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/2
07:00 am
tlsa
Form 6-K Tiziana Life Sciences For: Dec 02
Medium
Report
Form 6-K Tiziana Life Sciences For: Dec 02
11/25
08:30 am
tlsa
Form 6-K Tiziana Life Sciences For: Nov 25
Medium
Report
Form 6-K Tiziana Life Sciences For: Nov 25
11/14
01:11 pm
tlsa
Form SCHEDULE 13G/A Tiziana Life Sciences Filed by: Chernett Jorey
Neutral
Report
Form SCHEDULE 13G/A Tiziana Life Sciences Filed by: Chernett Jorey
11/13
08:31 am
tlsa
Form 6-K Tiziana Life Sciences For: Nov 13
High
Report
Form 6-K Tiziana Life Sciences For: Nov 13
10/29
07:00 am
tlsa
Form 6-K Tiziana Life Sciences For: Oct 29
Medium
Report
Form 6-K Tiziana Life Sciences For: Oct 29
10/28
10:56 am
tlsa
Form SCHEDULE 13G Tiziana Life Sciences Filed by: Fonda Laura Natalia Monica
Medium
Report
Form SCHEDULE 13G Tiziana Life Sciences Filed by: Fonda Laura Natalia Monica
10/3
04:30 pm
tlsa
Form 6-K Tiziana Life Sciences For: Oct 03
Medium
Report
Form 6-K Tiziana Life Sciences For: Oct 03
9/30
08:31 am
tlsa
Form 6-K Tiziana Life Sciences For: Sep 30
Low
Report
Form 6-K Tiziana Life Sciences For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/9
Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies
56.7%
3/11 Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million 28.3%
6/3 Form 6-K Tiziana Life Sciences For: Jun 03 21.4%
3/13 Form 6-K Tiziana Life Sciences For: Mar 13 9.5%
7/1 Form 6-K Tiziana Life Sciences For: Jul 01 9.2%
7/22 Form 6-K Tiziana Life Sciences For: Jul 22 9.0%
9/4 Form 6-K Tiziana Life Sciences For: Sep 04 8.6%
4/24 Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia 5.7%
3/20 Tiziana Life Sciences PLC (NASDAQ: TLSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.1%
5/28 Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational 2.7%
3/11 Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million 28.3%
6/3 Form 6-K Tiziana Life Sciences For: Jun 03 21.4%
3/13 Form 6-K Tiziana Life Sciences For: Mar 13 9.5%
7/1 Form 6-K Tiziana Life Sciences For: Jul 01 9.2%
7/22 Form 6-K Tiziana Life Sciences For: Jul 22 9.0%
9/4 Form 6-K Tiziana Life Sciences For: Sep 04 8.6%
4/24 Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia 5.7%
3/20 Tiziana Life Sciences PLC (NASDAQ: TLSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.1%
5/28 Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational 2.7%
TOP News Decliners
1/9
Form 6-K Tiziana Life Sciences For: Jan 09
-39.2%
4/9 Form 6-K Tiziana Life Sciences For: Apr 09 -25.3%
4/15 Form 6-K Tiziana Life Sciences For: Apr 15 -14.9%
2/14 Form FWP Tiziana Life Sciences Filed by: Tiziana Life Sciences plc -12.1%
8/5 Form F-1 Tiziana Life Sciences -10.6%
4/1 Form 6-K Tiziana Life Sciences For: Apr 01 -10.0%
4/14 Form 6-K Tiziana Life Sciences For: Apr 14 -9.9%
10/30 Form 6-K Tiziana Life Sciences For: Oct 30 -8.2%
4/27 Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses -7.9%
11/19 Tiziana Life Sciences PLC (NASDAQ: TLSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.1%
4/9 Form 6-K Tiziana Life Sciences For: Apr 09 -25.3%
4/15 Form 6-K Tiziana Life Sciences For: Apr 15 -14.9%
2/14 Form FWP Tiziana Life Sciences Filed by: Tiziana Life Sciences plc -12.1%
8/5 Form F-1 Tiziana Life Sciences -10.6%
4/1 Form 6-K Tiziana Life Sciences For: Apr 01 -10.0%
4/14 Form 6-K Tiziana Life Sciences For: Apr 14 -9.9%
10/30 Form 6-K Tiziana Life Sciences For: Oct 30 -8.2%
4/27 Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses -7.9%
11/19 Tiziana Life Sciences PLC (NASDAQ: TLSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: